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Cell lines derived from patients with leukemia are used in many molecular biology studies. Here we report the cytogenetic
analysis of the THP-1 cell line using G-banding, fluorescence in situ hybridization (FISH), and spectral karyotyping (SKY), and
the molecular characterization of the MLL-AF9 rearrangement by RT-PCR. The THP-1 cell line was established from the
peripheral blood of a 1-year-old boy with acute monocytic leukemia (AML-M5). THP-1 is near-diploid and consists of two
related subclones with a number of aberrations, including the t(9;11), associated with AML M5. The use of FISH allowed us
to identify and characterize otherwise hidden cytogenetic rearrangements, which include duplication of the 39 portion of MLL
in the derivative 9 chromosome and a deletion of the 59 portion of the AF9 gene involved in the translocation. In addition to
confirming the FISH results, SKY allowed for a more precise characterization of the karyotype of THP-1 and allowed us to
identify other abnormalities in this cell line, including der(1)t(1;12), der(20)t(1;20), deletions 6p, 12p, and 17p, trisomy 8, and
monosomy 10. Sequencing of the RT-PCR product showed a direct in-frame fusion product on the derivative chromosome
11 between exon 6 (exon 9) of MLL and exon 5 of AF9, which is most commonly involved in MLL-AF9 translocations. This study
demonstrates that combining different techniques to achieve a more precise characterization of the THP-1 cell line provides
important information that will be valuable for understanding the critical events required for leukemogenesis.
© 2000 Wiley-Liss, Inc.
INTRODUCTION
The t(9;11)(p22;q23) is a recurring abnormality
in acute myeloid leukemia (AML), usually M4 and
M5. The translocation results in the fusion of MLL
at 11q23 and the AF9 gene at 9p22 (Iida et al.,
1993; Nakamura et al., 1993). Molecular cloning
indicates that the breakpoint junctions in this
translocation may be complex, with duplications or
deletions of up to several hundred base pairs oc-
curring at the junctions (Nakamura et al., 1993;
Super et al., 1997).
With few exceptions, hematologic malignancies
with a rearranged MLL gene exhibit biological
characteristics that make them poorly responsive to
conventional therapies. For AML, it appears that
the prognostic effect may depend on the particular
MLL translocation partner involved (DiMartino
and Cleary, 1999). The prognosis for children and
adults with AML and t(9;11) is better than for
patients with other abnormalities of 11q23, espe-
cially with intensive treatment during remission
(Martinez-Clement, et al., 1995; Mrozek et al.,
1997; Grimwade et al., 1998; Swansbury et al.,
1998). In the t(9;11) group, the presence of trisomy
8 was associated with a more favorable outcome,
perhaps because of an inverse relationship with the
presence of central nervous system disease (Swans-
bury et al., 1998).
The THP-1 cell line carrying a t(9;11) was
established from the peripheral blood of a 1-year-
old boy with acute monocytic leukemia (AML-
M5) (Tsuchiya et al., 1980). This cell line is
known to have a t(9;11) (Drexler et al., 1995),
but has not been molecularly characterized or
studied in detail using newer cytogenetic tech-
niques.
To characterize the chromosomal abnormalities
more fully, we studied the THP-1 cell line using
three different techniques: G-banding, fluores-
cence in situ hybridization (FISH), and spectral
karyotyping (SKY). In order to determine whether
a potentially productive MLL-AF9 fusion was
formed, we performed a molecular analysis to de-
tect this rearrangement.
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MATERIALS AND METHODS
FISH Probes
MLL was analyzed using an MLL probe (Oncor,
Gaithersburg, MD) and an LSI MLL dual-color
probe (Vysis, Downers Grove, IL). The latter
probe consists of a 350-kb portion centromeric of
the MLL gene breakpoint cluster region (BCR)
labeled in Spectrum Green and a 190-kb portion
largely telomeric of the BCR labeled in Spectrum
Orange. A cosmid contig that contained AF9 was
used to analyze this gene (Strissel et al., 2000). The
order of these probes is 59 (centromeric) 34A5-
232G8-92F5-C48-55E5-213A7 (telomeric) 39 (Fig.
1). Additional FISH experiments were performed
using centromere-specific probes (CEP) for chro-
mosomes 9 and 12 (Vysis).
FISH
G-banding and FISH analysis were performed as
previously described (Rowley et al., 1990). The
karyotype was described according to ISCN (1995).
The probes were labeled with biotin-11-dUTP or
digoxigenin-11-dUTP (Boehringer Mannheim Bio-
chemicals, Indianapolis, IN) using nick translation.
The biotin-labeled probes were detected with
FITC-conjugated avidin. The digoxigenin-labeled
probes were detected with rhodamine-conjugated
sheep antidigoxigenin antibodies (Boehringer
Mannheim Biochemicals). Chromosomes were
identified using counterstaining with 496-dia-
midino-2-phenylindole dihydrochloride (DAPI).
Images of the hybridized cells were captured
with a liquid-cooled, charge-coupled device camera
(Photometrics, Tucson, AZ). Separate gray-scale
images for the DAPI and the fluorescein isothio-
cyanate fluorescence were acquired. The images
were merged using Adobe Photoshop (Adobe Sys-
tems, San Jose, CA) on a Macintosh computer (Ap-
ple Computers, Cupertino, CA).
SKY
The SKY probe mixture and hybridization re-
agents were obtained from Applied Spectral Imag-
ing (Carlsbad, CA). Slides for spectral karyotyping
were hybridized with the probe cocktail as previ-
ously described (Rowley et al., 1999) for 2 days at
37°C. Ten metaphase cells were captured and an-
alyzed using the SD200 system (Applied Spectral
Imaging).
RT-PCR
Total RNA was extracted using TriReagent
(Molecular Research Center, Cincinnati, OH).
First-strand cDNA was generated with the cDNA
Cycle kit (Invitrogen) and was used as template for
PCR with primers EX-5-1 (MLLBCRT1) (59-
GGATCCTGCCCCAAAGAAAAGCAGTAGT-
GAGCC-39) and AF9-AS4 (59-CAGGATGTTC-
CAGATGTTTCCACT-39) in the first round, and
EX-5-2 (Sma 1300T) (59-GCCAGCACTGGT-
CATCCCGCCTCAG-39) and AF9-AS3 (59-
TTCACGATCTGCTGCAGAATGTGTCT-39)
in the second round (Super et al., 1997). The RT-
PCR products were cloned into the pCR 2.1 vector
using the TA cloning kit (Invitrogen) and were
sequenced using an ABI 377 sequencer with d-
Rhodamine terminator sequencing kit (Perkin
Elmer, Warrington, U.K.).
Figure 1. Schematic diagram of the cDNA of the AF9 gene showing the location of the cosmid probes
used for FISH relative to the cDNA sequence. The breakpoint in AF9 is in C48.
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RESULTS AND DISCUSSION
Cytogenetic analysis after performing the differ-
ent techniques showed two related near-diploid
clones: 49,XY,1der(1)del(1)(p22p36)t(1;12)(p36;
q11),del(6)(p21),1del(6)(p21),18,1der(9)t(9;
11)(p22;q23)t(9;11)(q12;q23),210,der(11)t(9;
11)(p22;q23),del(12)(q11),del(17)(p11),der(20)-
ins(20;1)(p12;p22p36)[13]/48,idem,2del(12)(q11)[7].
Using the LSI MLL dual color probe (Vysis), we
detected a 39 MLL duplication in the der(9) chro-
mosome. 59 MLL remained on the der(11) chromo-
some (Fig. 2A). The der(9) is a short chromosome
with the 9p22 band fused to the 39 portion of the
MLL gene. Unexpectedly, there is a deletion in
band 9q12, which is fused to another copy of 39
MLL. These results were confirmed with the Oncor
MLL probe (Fig. 2B and C). The centromere probe
CEP 9 confirmed that this chromosome was a der(9).
FISH analysis with the AF9 contig cosmids
showed the presence of cosmids 34A5, 232G8, and
92F5 only in the normal chromosomes 9. Cosmids
C48 and 55E5 were found in both normal chromo-
somes 9 and in the der(11) (Fig. 2B). Cosmid 34A5
was present only on the normal chromosome 9
(Fig. 2C). Thus, the MLL-AF9 fusion on the
der(11) chromosome was confirmed using FISH,
and the changes affecting AF9 were shown to be
very complex with deletion of AF9 from the der(9)
chromosome. Analysis of 10 cells with SKY con-
firmed the FISH results and allowed for a more
complete characterization of the karyotype of the
cell line (Fig. 3).
Figure 2. FISH analysis of the MLL-AF9 rearrangement. A: LSI MLL
dual-color probe showing the 39 MLL duplication on the der(9) (red); 59
MLL remains on the der(11) chromosome (green). The normal 11 has
a yellow fusion signal. B: Oncor MLL probe (red) and cosmid C48 (AF9)
(green). The MLL probe labels the normal 11 and the der(11). Cosmid
C48 was found in both normal chromosomes 9 and in the der(11). C:
Labeling with the Oncor MLL probe is as in B. The AF9 cosmid 34A5
(green) was detected only in the normal chromosome 9. This broken
metaphase cell contains only one chromosome 9.
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We analyzed the THP-1 cell line using nested
RT-PCR to determine whether an MLL-AF9 fu-
sion was formed. Two amplification products of
approximately 500 bp and 400 bp were observed in
the second round when the MLL exon 5 (exon 8)
and the AF9 primers were used. MLL exons were
numbered initially by Gu et al. (1992). Lochner et
al. (1996) identified three additional exons so the
new numbers are indicated in parenthesis. The
amplification products were cloned and sequenced.
Sequencing showed that the larger fragment was a
direct in-frame fusion between exon 6 (exon 9) of
MLL and exon 5 of AF9 (Strissel et al., 2000)
previously referred to as site A by Yamamoto et al.
(1994). The smaller fragment showed fusion of
MLL exon 5 (exon 8) to the same AF9 exon 5,
which would not be translated into a fusion protein
because the fusion resulted in an in-frame stop
codon 2 bp after the end of MLL exon 5 (Fig. 4).
This AF9 exon is located in cosmid C48; the ma-
jority of AF9 breakpoints occur in intron 4 as is
shown for this cell line (Strissel et al., 2000).
Thus, a more complete characterization of the
THP-1 cell line was achieved by using all four
Figure 3. Spectral karyotype of THP-1. DAPI stained metaphase cell from the THP-1 cell line (upper
left) and classified spectral image of the same cell (upper right). Bottom: Spectral karyotype of same cell.
See text for karyotype.
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techniques in combination. Several new pieces of
information were obtained. Although complex
MLL-AF9 rearrangements with duplications and
deletions have been described (Nakamura et al.,
1993; Super et al., 1997), the 39 MLL duplication
and the fusion of 9q12 to 39 MLL have not been
reported previously. It will be important to deter-
mine whether the other 39 MLL fusion results in a
product potentially capable of being expressed and
of having an effect on the transformation process.
Swansbury et al. (1998) reported that it may be
possible to identify further subgroups of t(9;11)
patients with a relatively better or worse prognosis
based on karyotypic changes. Our results show that
SKY provides a useful tool to characterize the
karyotype more completely. We were able to iden-
tify several other chromosomal abnormalities in
addition to the t(9;11), including der(1)t(1;12),
der(20)t(1;20), deletions 6p, 12p, and 17p, trisomy
8, and monosomy 10.
Using an MLL-AF9 knock in mouse, Dobson et
al. (1999) reported that secondary mutations are
necessary for malignancy associated with this gene
fusion. Knowledge of the secondary changes in this
cell line could be useful in order to study these
changes at molecular level.
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